Department of Cardiology, Ghent University Hospital, Ghent, Belgium.
EuroIntervention. 2014 Jan 22;9(9):1095-101. doi: 10.4244/EIJV9I9A184.
The relationship between the predictive performance of the TIMI risk score for STEMI and gender has not been evaluated in the setting of primary PCI (pPCI). Here, we compared in-hospital mortality and predictive performance of the TIMI risk score between Belgian women and men undergoing pPCI.
In-hospital mortality was analysed in 8,073 (1,920 [23.8%] female and 6,153 [76.2%] male patients) consecutive pPCI-treated STEMI patients, included in the prospective, observational Belgian STEMI registry (January 2007 to February 2011). A multivariable logistic regression model, including TIMI risk score variables and gender, evaluated differences in in-hospital mortality between men and women. The predictive performance of the TIMI risk score according to gender was evaluated in terms of discrimination and calibration. Mortality rates for TIMI scores in women and men were compared. Female patients were older, had more comorbidities and longer ischaemic times. Crude in-hospital mortality was 10.1% in women vs. 4.9% in men (OR 2.2; 95% CI: 1.82-2.66, p<0.001). When adjusting for TIMI risk score variables, mortality remained higher in women (OR 1.47, 95% CI: 1.15-1.87, p=0.002). The TIMI risk score provided a good predictive discrimination and calibration in women as well as in men (c-statistic=0.84 [95% CI: 0.809-0.866], goodness-of-fit p=0.53 and c-statistic=0.89 [95% CI: 0.873-0.907], goodness-of-fit p=0.13, respectively), but mortality prediction for TIMI scores was better in men (p=0.02 for TIMI score x gender interaction).
In the Belgian STEMI registry, pPCI-treated women had a higher in-hospital mortality rate even after correcting for TIMI risk score variables. The TIMI risk score was effective in predicting in-hospital mortality but performed slightly better in men. The database was registered with clinicaltrials.gov (NCT00727623).
TIMI 风险评分对 ST 段抬高型心肌梗死(STEMI)的预测性能与性别之间的关系尚未在直接经皮冠状动脉介入治疗(pPCI)中得到评估。在此,我们比较了接受 pPCI 治疗的比利时女性和男性患者的 TIMI 风险评分的院内死亡率和预测性能。
我们分析了前瞻性观察性比利时 STEMI 注册研究(2007 年 1 月至 2011 年 2 月)中连续 8073 例(女性 1920 例[23.8%],男性 6153 例[76.2%])接受 pPCI 治疗的 STEMI 患者的院内死亡率。多变量逻辑回归模型包括 TIMI 风险评分变量和性别,评估了男性和女性之间院内死亡率的差异。根据性别评估 TIMI 风险评分的预测性能,包括区分度和校准度。比较了 TIMI 评分在女性和男性中的死亡率。女性患者年龄较大,合并症更多,缺血时间更长。女性的院内死亡率为 10.1%,男性为 4.9%(OR 2.2;95%CI:1.82-2.66,p<0.001)。调整 TIMI 风险评分变量后,女性的死亡率仍然更高(OR 1.47,95%CI:1.15-1.87,p=0.002)。TIMI 风险评分在女性和男性中均提供了良好的预测区分度和校准度(c 统计量=0.84[95%CI:0.809-0.866],拟合优度 p=0.53 和 c 统计量=0.89[95%CI:0.873-0.907],拟合优度 p=0.13),但 TIMI 评分的死亡率预测在男性中更好(TIMI 评分×性别交互作用的 p=0.02)。
在比利时 STEMI 注册研究中,即使校正 TIMI 风险评分变量后,接受 pPCI 治疗的女性患者的院内死亡率仍然较高。TIMI 风险评分能有效预测院内死亡率,但在男性中的效果稍好。该数据库已在 clinicaltrials.gov(NCT00727623)注册。